MK-5475-013
Frespaciguat INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat in Adults With PH-COPD
Active, Not Recruiting
Trial Purpose
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
View full trial information on Clinicaltrials.gov
 |
National Trial Reference Number | NCT05612035 |
 |
MSD Protocol ID |
MK-5475-013 |
 |
Conditions |
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension |
 |
Age Range |
40 – 85 |
 |
Sex | ALL |
 |
Trial Phase | 2 |
 |
Start Date End Date |
2023-03-16 2029-10-08 |
Study Details
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial.
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Trial Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participantsResearch participantIn clinical research, a person who qualifies and agrees to participate in a study. Also called volunteer, trial participant. – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fir and you are interested in taking part, take the next step to see if you are eligible.
Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
To learn more, call 1-888-577-8839